Last reviewed · How we verify

NCT00008242

A Phase II Clinical Trial Of Thalidomide, Adramycin And Dexamethasone (TAD) As Initial Therapy For The Treatment Of Multiple Myeloma

Completed Phase 2 Last updated 6 March 2013
What this trial tests

Phase 2 trial testing dexamethasone in Multiple Myeloma and Plasma Cell Neoplasm. Completed in 1 January 2006.

Timeline
1 August 2000
Primary endpoint
1 January 2006
1 January 2006

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Primary purposetreatment
Start date1 August 2000
Primary completion1 January 2006
Estimated completion1 January 2006
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma and Plasma Cell Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining thalidomide with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of thalidomide, doxorubicin, and dexamethasone in treating patients who have untreated stage II or stage III multiple myeloma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of dexamethasone

Trials testing the same drug.

Other recruiting trials for Multiple Myeloma and Plasma Cell Neoplasm

Currently open trials in the same condition.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00008242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing